# Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

> **NCT06387134** · NA · UNKNOWN · sponsor: **Henan University of Traditional Chinese Medicine** · enrollment: 40 (estimated)

## Conditions studied

- Early Stage Lung Adenocarcinoma

## Interventions

- **DRUG:** Lifei Xiaoji Wan
- **DRUG:** Conventional treatment with Western medicine

## Key facts

- **NCT ID:** NCT06387134
- **Lead sponsor:** Henan University of Traditional Chinese Medicine
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2025-01-01
- **Final completion:** 2025-05-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06387134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06387134, "Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06387134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*